5:34 PM
 | 
Apr 10, 2013
 |  BC Extra  |  Company News

Aeterna partners with CRO on Zoptarelin Phase III

Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) partnered with CRO Ergomed Clinical Research Ltd. (London, U.K.) to co-develop Zoptarelin doxorubicin acetate ( AEZS-108) to treat endometrial cancer. Ergomed will be responsible for 30% of the costs for...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >